Akorn (AKRX) has been under a strong bear grip, hence the stock is down -0.93% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.63% in the past 1 week. The stock has risen by 4.18% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.94% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 2.62% and the 50-Day Moving Average is 5.33%.The 200 Day SMA reached 1.23% Akorn, Inc. has dropped 1.76% during the last 3-month period . Year-to-Date the stock performance stands at -23.85%.
Akorn (AKRX) : 8 investment research analysts covering Akorn (AKRX) have an average price target of $35.88 for the near short term. The highest target price given by the Brokerage Firm to the stock is $40 and the lowest target is $31 for the short term. Analysts expect the variance to be within $3.23 of the average price.
For the current week, the company shares have a recommendation consensus of Buy. Akorn (NASDAQ:AKRX): The stock opened at $28.3 and touched an intraday high of $28.695 on Friday. During the day, the stock corrected to an intraday low of $28.27, however, the bulls stepped in and pushed the price higher to close in the green at $28.41 with a gain of 0.07% for the day. The total traded volume for the day was 1,523,552. The stock had closed at $28.41 in the previous trading session.
Akorn Inc. (Akorn), together with its wholly owned subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products. The Company specializes in sterile and non-sterile dosage forms, including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company operates in two segments: Prescription Pharmaceuticals, which is engaged in the sale of branded and generic prescription pharmaceuticals, and Consumer Health, which is engaged in the sale of branded and private label consumer and animal health products. The Company operates pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York, and Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, and an additional warehousing facility in Amityville, New York.